Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus neoadjuvant radiotherapy in resectable esophageal squamous cell carcinoma
ChiCTR2500105054Phase 2Completed
- Sponsor
- Shandong First Medical University
- Start
- Jun 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Shandong First Medical University. Primary endpoint: Pathologic complete response rate (pCR). Started Jun 2025; status: completed.
02
Drugs
cadonilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500105054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105054.